Janssen returns NASH candidate rights to Arrowhead

16 February 2023
arrowhead-company

US biotech Arrowhead Pharmaceuticals (Nasdaq: AEWR) yesterday revealed receiving a written notice from US healthcare giant Johnson & Johnson’s (NYSE: JNJ) Janssen unit that it has terminated its rights to JNJ-75220795, now called ARO-PNPLA3, under the October 2018 research collaboration and option agreement, as part of J&J’s strategic R&D portfolio review.

The deal could have earned Arrowhead as much as $3.7 billion including milestone and royalty payments.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory



Companies featured in this story

More ones to watch >






Company Spotlight



More Features in Biotechnology